Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,065.00-1.18%ETH$2,470.33+0.03%GOLD$4,386.00-0.48%OIL$99.65-2.76%
Smart Investors Daily
XF

NASDAQ · XFOR

X4 Pharmaceuticals, Inc.

Healthcare · Biotechnology

$3.40

Down-$0.20 (-5.56%)

Updated Sep 11, 2026, 8:43 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
44.21M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$2.80 – $4.83
Volume
2.57M
Avg. volume
894.59K

Price performance

XFOR price history

1M range · 20 trading sessions · Daily adjusted prices

XFOR closed at $3.40 after 20 trading sessions, down 20.75% for the selected period.

Last close
$3.40
Period change
-20.75%
Period low
$3.40
Period high
$4.30
Daily close
View OHLC price history
XFOR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$3.60$3.675$3.31$3.402.57M
Sep 9, 2026$3.50$3.67$3.45$3.601.4M
Sep 8, 2026$4.00$4.1254$3.19$3.5052.32M
Sep 4, 2026$4.01$4.08$4.00$4.04168.16K
Sep 3, 2026$4.06$4.0691$3.99$4.04409.44K
Sep 2, 2026$4.10$4.17$4.015$4.04360.96K
Sep 1, 2026$3.97$4.11$3.97$4.07203.87K
Aug 31, 2026$4.02$4.10$4.00$4.04245.89K
Aug 28, 2026$4.22$4.23$4.00$4.04356.38K
Aug 27, 2026$4.18$4.39$4.145$4.23597.24K
Aug 26, 2026$4.16$4.23$4.075$4.17707.14K
Aug 25, 2026$4.05$4.18$3.995$4.16390.76K
Aug 24, 2026$4.03$4.095$3.94$4.05299.17K
Aug 21, 2026$4.05$4.175$4.005$4.041.22M
Aug 20, 2026$4.12$4.22$3.99$4.03561.21K
Aug 19, 2026$4.25$4.35$4.14$4.16406.05K
Aug 18, 2026$4.27$4.32$4.145$4.21362.09K
Aug 17, 2026$4.20$4.335$4.13$4.301.1M
Aug 14, 2026$4.26$4.33$4.05$4.22840.93K
Aug 13, 2026$4.28$4.455$4.19$4.291.13M

Latest XFOR news

The latest Smart Investors Daily articles mentioning XFOR.

Stock researchCompany · Overview

XFOR research

Overview

Company profile and research snapshot.

Company profile

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.75
Implied upside
—
Analysts
—
XFOR recent ratings
DateFirmRatingTarget
Jul 10, 2026Wells FargoOverweight—
Jun 2, 2026Leerink PartnersOutperform—
Mar 9, 2026GuggenheimBuy—
Dec 5, 2025StifelBuy—
Nov 10, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmac

Yahoo · Sep 8, 2026

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the positive outcome of its Type C Meeting with the U.S. Food and Drug Administration (FDA) related to the global 4WARD Phase 3 clinical trial. The pu

Yahoo · Sep 1, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By